• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Urinary Tract Infection Market

    ID: MRFR/MED/4680-CR
    164 Pages
    Kinjoll Dey
    February 2021

    Urinary Tract Infection Market Research Report Information InApplicationation By Drug Class (Ouinolones, Beta & Cephalosporins, Aminoglycosides, Penicillin, and Azoles), By Application (Urethritis, Cystitis and Pyelonephritis), By Pathogen (Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis and Enterococcus faecalis), By End-User (Hospitals, Clinics and Self-Administered), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Urinary Tract Infection Market Research Report - Global Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    Urinary Tract Infection Market Summary

    As per Market Research Future Analysis, the urinary tract infection (UTI) market was valued at USD 10.6 billion in 2023 and is projected to reach USD 16.3 billion by 2032, growing at a CAGR of 2% from 2023 to 2032. The market is driven by increasing UTI prevalence, technological advancements in diagnostics, and a growing geriatric population. Women, particularly postmenopausal, are more affected due to changes in vaginal flora. The introduction of home testing kits and portable devices is expected to enhance market uptake. However, challenges such as medication side effects and lack of awareness in developing regions may hinder growth.

    Key Market Trends & Highlights

    Key trends influencing the UTI market include technological advancements and demographic shifts.

    • Market size in 2023: USD 10.6 billion; projected to grow to USD 16.3 billion by 2032.
    • CAGR during forecast period (2023-2032): 2%.
    • North America accounted for USD 3.9 billion in 2022, holding around 45.80% market share.
    • Cystitis segment projected to be the fastest-growing application segment during 2023-2030.

    Market Size & Forecast

    2023 Market Size USD 10.6 Billion
    2032 Market Size USD 16.3 Billion
    CAGR (2023-2032) 2%

    Major Players

    Key players include Pfizer Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, Bayer AG, and Merck & Co. Inc.

    Urinary Tract Infection Market Trends

      • Rising Use of Urinary Catheters and Other Drainage Devices to propel market growth

    With the rising incidence of chronic kidney diseases such as bladder cancer and renal failure, Patients use catheters and other drainage devices. Easier access to patients with urinary catheters and Complicated urinary tract infections. According to the World Health Organization (WHO), the risk of bacteriuria is approximately 5% per day. Of patients using urinary catheters, 40% had nosocomial infections. Certain factors include prolonged catheterization duration, lack of systemic antibiotic therapy, bacterial Colonization in the drainage bag, rapid fata underlying disease, etc. May lead to catheter-related urinary tract infections.

    Therefore, increased use of urinary catheters promotes the growth of the urinary tract Infection Treatment Market.

    Women are more prone to UTIs than men. Incidence in adult females increases with age. Infection rates are higher in postmenopausal women because of changes in the vaginal flora that provide a favorable environment for the growth of certain pathogens.

    Introduction of portable hand-held devices and availability of home sample collection kits and self-test kits for UTI testing are among the factors likely to boost adoption. For example, in May 2020, Healthy.io Ltd. launched a home testing kit in the UK. Moreover, point-of-care detection of UTIs will be a key growth area, which is expected to increase investments by companies. In addition, researchers are developing technologically advanced disease diagnostic products that are expected to be commercialized in space in the next few years. In January 2020, engineers at the University of Bath developed the UTI test using smartphone cameras.

    They claim it can detect the presence of E. coli in a urine sample in less than 25 minutes. Thus, this factor is driving the market CAGR. Thus, it is anticipated that this aspect will accelerate Urinary Tract Infection market revenue globally.

    The rising prevalence of urinary tract infections, particularly among women, underscores the urgent need for innovative treatment options and preventive measures in the healthcare landscape.

    Centers for Disease Control and Prevention (CDC)

    Urinary Tract Infection Market Drivers

    Rising Prevalence of UTIs

    The Global Urinary Tract Infection Market Industry experiences a notable increase in demand due to the rising prevalence of urinary tract infections. Statistics indicate that approximately 50 to 60 percent of women will experience at least one UTI in their lifetime. This growing incidence is attributed to factors such as increased sexual activity, hormonal changes, and the aging population. As the global population ages, the susceptibility to UTIs is expected to rise, thereby driving market growth. The market is projected to reach 10.8 USD Billion in 2024, reflecting the urgent need for effective treatment options and preventive measures.

    Increased Awareness and Education

    The Global Urinary Tract Infection Market Industry benefits from heightened awareness and education surrounding urinary health. Public health campaigns and educational initiatives aim to inform individuals about UTI symptoms, risk factors, and preventive measures. This increased awareness encourages individuals to seek timely medical attention, thereby driving demand for diagnostic and therapeutic products. Furthermore, healthcare providers are increasingly focusing on educating patients about lifestyle modifications that can reduce UTI risk. As a result, the market is likely to experience sustained growth, supported by an informed population that prioritizes urinary health.

    Chart Representation of Market Growth

    The Global Urinary Tract Infection Market Industry is projected to experience substantial growth over the coming years. The market is expected to reach 10.8 USD Billion in 2024 and is anticipated to grow to 17.3 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 4.38% from 2025 to 2035. This growth trajectory underscores the increasing demand for effective UTI management solutions and highlights the importance of ongoing research and development in the field.

    Advancements in Diagnostic Technologies

    Innovations in diagnostic technologies significantly contribute to the growth of the Global Urinary Tract Infection Market Industry. Enhanced diagnostic tools, such as rapid urine tests and molecular diagnostics, facilitate quicker and more accurate identification of UTIs. These advancements not only improve patient outcomes but also streamline healthcare processes. For instance, the adoption of point-of-care testing allows for immediate diagnosis and treatment initiation, reducing the burden on healthcare systems. As healthcare providers increasingly adopt these technologies, the market is expected to expand, with projections indicating a growth to 17.3 USD Billion by 2035.

    Growing Demand for Antimicrobial Treatments

    The Global Urinary Tract Infection Market Industry is witnessing a growing demand for antimicrobial treatments as antibiotic resistance becomes a pressing concern. The emergence of multidrug-resistant bacteria necessitates the development of novel therapeutic options. Pharmaceutical companies are investing in research and development to create new antibiotics and alternative treatments, such as bacteriophage therapy. This trend is crucial for addressing the challenges posed by resistant strains and ensuring effective management of UTIs. The market's expansion is further supported by the increasing prevalence of complicated UTIs, which require more advanced treatment strategies.

    Market Segment Insights

    Urinary Tract Infection Drug Class Insights

    Based on Drug Class, the market segments of urinary tract infection includes quinolones, beta & cephalosporins, aminoglycosides, penicillin and azoles. The quinolones segment held the majority share in 2022 in the Urinary Tract Infection market data. Many doctors advise their patients to take quinolones promptly to clear up the infection. Moreover, the quinolones industry is expected to grow at the fastest CAGR during the forecast period.

    Figure 2: Urinary Tract Infection Market, by Drug Class, 2022 & 2030 (USD Billion)Urinary Tract Infection Market, by Drug Class

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Urinary Tract Infection Application Insights

    Based on application, the Urinary Tract Infection market segmentation includes urethritis, cystitis and pyelonephritis. The cystitis segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2030. This can be attributed to the high incidence and recurrence rate of cystitis, the increasing number of product approvals, and the high number of diabetic patients more prone to cystitis. Globally, approximately 10 in 100 women develop acute cystitis each year, according to the NCBI's Epidemiology Report.

    Also, its recurrence rate is higher in women; half of those with cystitis will get cystitis again within a year.

    Urinary Tract Infection Pathogen Insights

    The market segmentation of Urinary Tract Infection, based on the pathogen, includes escherichia coli, staphylococcus saprophyticus, klebsiella pneumoniae, proteus mirabilis and enterococcus faecalis. The Escherichia coil segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2030. Healthcare providers are encouraging the increased incidence of community-acquired urinary tract infections caused by the Escherichia coli (E. Coil) pathogen due to the presence of antibiotics in patients. Therefore, stakeholders in the urinary tract infection treatment market must meet the growing demand for effective antibiotic drugs for UTIs caused by Escherichia coli pathogens.

    Urinary Tract Infection End User Insights

    The market data of Urinary Tract Infection, based on end users, includes hospitals, clinics and self-administered. The hospital segment dominated the market revenue of Urinary Tract Infection  in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. This is due to an increase in cases of hospital-acquired urinary tract infections. However, the diagnostic laboratories segment is projected to register the highest CAGR in 2031. Laboratory diagnosis is based on cultured colony counts, which reflect the concentration of organisms in the urine.

    May 2023: A prototype diagnostic sensor developed by UT Southwestern Medical Center researchers may one day allow people to confirm the presence of urinary tract infections (UTIs) without waiting for laboratory test results (which can take anywhere from 24 to 48 hours). Up to 85% accuracy in detecting a UTI is presently achieved by using the new method, which involves the detection and determination of the concentration of three protein biomarkers in urine.

    According to the study's authors, this approach has the potential to increase the diagnostic accuracy of existing electrochemical biosensors, leading to more targeted treatment and better health outcomes for patients. 

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Urinary Tract Infection market accounted for USD 3.9 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The region is experiencing a dramatic increase in innovations related to diagnostic methods for UTIs. During a routine UTI examination, a woman was observed to be infected with E. coli that showed resistance to last-resort antibiotics, according to a November 2020 paper by Pranita D.

    Tamma in Infectious Diseases Society of America, colistin.

    Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. 

    Figure 3: URINARY TRACT INFECTION MARKET SHARE BY REGION 2022 (%)URINARY TRACT INFECTION MARKET SHARE BY REGION

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe's Urinary Tract Infection market accounts for the second-largest market share. Factors such as an increase in the geriatric population, research & development programs, and high-class healthcare infrastructure are boosting demand in Germany's urinary cystitis management market. Moreover, the U.K. market of urinary tract infection held the largest market share, and the Germany market of urinary tract infection was the fastest-growing market in the region.

    Asia Pacific Urinary Tract Infection Market is expected to grow at the fastest CAGR from 2022 to 2030. The high growth rate can be attributed to rising disease incidence and the aging population. Increasing demand for cost-effective diagnostics and a growing population are important factors driving the market growth. Asia-Pacific markets such as Australia and South Korea already have a medical reimbursement system that covers UTI diagnostic testing. Further, the China market of urinary tract infection held the largest market share, and the India market of urinary tract infection was the fastest-growing market in the region.

    Key Players and Competitive Insights

    Major market players are spending a lot of money on R&D to increase their product lines, which will help the market growth of urinary tract infection even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Urinary Tract Infection industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

    One of the primary business strategies manufacturers adopt in the Urinary Tract Infection industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In recent years, Urinary Tract Infection industry has provided medicine with some of the most significant benefits. The Urinary Tract Infection markets major players such as Nestle, JM Smucker Company, The Kraft Heinz Company and Starbucks Urinary Tract Infection Company.

    Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's business areas include pharmaceuticals, consumer healthcare, agrochemicals, seeds and biotechnology products. In August 2021, the company announced the acquisition of division therapeutics, a US-headquartered biopharmaceutical company using novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics.

    Also, Merck & Co. was originally established in 1891 as the U.S. subsidiary of the Merck Group. Merck develops and manufactures pharmaceuticals, vaccines, biotherapeutics and animal health products. It has several blockbuster drugs or products, each generating revenue in 2020, including cancer immunotherapies, anti-diabetic drugs, and vaccines against HPV and chickenpox. In February 2023, Merck announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with standard-of-care chemotherapy (carboplatin and paclitaxel), met its primary endpoint of progression-free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.

    Key Companies in the Urinary Tract Infection Market market include

    Industry Developments

    October 2021:Spero Therapeutics Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for imipenem hydrobromide tablets for the treatment of complicated urinary tract infections (cUTI ), including those caused by pyelonephritis. Susceptible microorganisms.

    September 2021:BDR Pharma, one of India's leading generic pharmaceutical companies, launched biapenem to treat patients with intra-abdominal infection, lower respiratory tract infection or complicated urinary tract infection.

    Future Outlook

    Urinary Tract Infection Market Future Outlook

    The Global Urinary Tract Infection Market is projected to grow at a 4.38% CAGR from 2024 to 2035, driven by rising infection rates, increasing awareness, and advancements in diagnostics.

    New opportunities lie in:

    • Develop innovative antibiotic alternatives to combat resistance.
    • Leverage telehealth solutions for remote diagnosis and treatment.
    • Invest in personalized medicine approaches for UTI management.

    By 2035, the market is expected to demonstrate robust growth, reflecting evolving healthcare needs and technological advancements.

    Market Segmentation

    Urinary Tract Infection End-User Outlook (USD Billion, 2019-2030)

    • Hospitals
    • Clinics
    • Self-Administered

    Urinary Tract Infection Pathogen Outlook (USD Billion, 2019-2030)

    • Escherichia coli
    • Staphylococcus saprophyticus
    • Klebsiella pneumoniae
    • Proteus mirabilis
    • Enterococcus faecalis

    Urinary Tract Infection Regional Outlook (USD Billion, 2019-2030)

    • US
    • Canada
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East
    • Africa
    • Latin America

    Urinary Tract Infection Drug Class Outlook (USD Billion, 2019-2030)

    • Quinolones
    • Beta & Cephalosporins
    • Aminoglycosides
    • Penicillin
    • Azoles

    Urinary Tract Infection Application Outlook (USD Billion, 2019-2030)

    • Urethritis
    • Cystitis
    • Pyelonephritis

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 USD 10.6 billion
    Market Size 2024 USD 10.8 billion
    Market Size 2032 USD 16.31 billion
    Compound Annual Growth Rate (CAGR) 2% (2023-2032)
    Base Year 2022
    Market Forecast Period 2023-2032
    Historical Data 2018 - 2021
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Drug Class, Application, Pathogen, End-User and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The U.S, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Nestle, JM Smucker Company, The Kraft Heinz Company and Starbucks Urinary Tract Infection Company
    Key Market Opportunities Increase in focus on the development of novel drugs
    Key Market Dynamics High prevalence of urinary tract infection across the globe Increasing prevalence of diabetes and increasing geriatric population

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    How much is the urinary tract infection market?

    The urinary tract infection market size was valued at USD 10.6 Billion in 2023.

    What is the growth rate of the urinary tract infection market?

    The market is projected to grow at a CAGR of  2% from 2023-2032.

    Which region held the largest market share in the urinary tract infection market?

    North America had the largest share of the market

    Who are the key players in the urinary tract infection market?

    The key players in the market are Pfizer Inc., Teva Pharmaceuticals, Novo Nordisk A/S, GlaxoSmithKline plc, Bayer AG and Novartis Ag urinary tract infection Company.

    Which Drug Class led the urinary tract infection market?

    Quinolones dominated the market in 2022.

    Which end-user had the largest market share in the urinary tract infection market?

    The hospitals had the largest share of the market.

    1. EXECUTIVE SUMMARY
      1. MARKET ATTRACTIVENESS ANALYSIS 18
    2. MARKET INTRODUCTION
      1. DEFINITION 19
      2. SCOPE OF THE STUDY 19
      3. RESEARCH OBJECTIVE 19
      4. MARKET STRUCTURE 19
      5. ASSUMPTIONS & LIMITATIONS 20
    3. RESEARCH METHODOLOGY
      1. DATA MINING 21
      2. SECONDARY RESEARCH 22
      3. PRIMARY
    4. RESEARCH 23
      1. BREAKDOWN OF PRIMARY RESPONDENTS 24
      2. FORECASTING
    5. TECHNIQUES 25
      1. RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26
        1. BOTTOM-UP APPROACH 27
        2. TOP-DOWN APPROACH 27
      2. DATA TRIANGULATION 28
      3. VALIDATION 28
    6. MARKET DYNAMICS
      1. OVERVIEW 29
      2. DRIVERS 30
        1. INCREASING PREVALENCE
    7. OF DIABETES AND KIDNEY STONES 30
      1. LAUNCH OF COMBINATION DRUGS 30
      2. RESTRAINTS 31
        1. COMPLEX REGULATORY REQUIREMENTS 31
      3. OPPORTUNITIES 32
        1. FOCUS ON EMERGING ECONOMIES AND BOOSTING
    8. R&D 32
    9. MARKET FACTOR ANALYSIS
      1. VALUE CHAIN ANALYSIS
        1. R&D AND DESIGNING 34
        2. MANUFACTURING 34
        3. DISTRIBUTION & SALES 34
        4. POST-SALES SERVICES 34
      2. PORTER’S FIVE FORCES MODEL 35
        1. BARGAINING POWER
    10. OF SUPPLIERS 36
      1. BARGAINING POWER OF BUYERS 36
    11. THREAT OF NEW ENTRANTS 36
      1. THREAT OF SUBSTITUTES 36
    12. RIVALRY 36
      1. IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION
    13. MARKET 37
      1. OVERVIEW 37
        1. IMPACT ON SUPPLY CHAIN 37
        2. IMPACT ON PRODUCTION 38
    14. GLOBAL URINARY TRACT INFECTION
    15. MARKET BY DRUG CLASS
      1. OVERVIEW 40
      2. QUINOLONES 42
      3. Β-LACTAM & CEPHALOSPORINS 43
      4. AMINOGLYCOSIDES
      5. PENICILLIN 44
      6. AZOLES 45
    16. GLOBAL URINARY
    17. TRACT INFECTION MARKET BY APPLICATION
      1. OVERVIEW 46
    18. URETHRITIS 47
      1. CYSTITIS 48
      2. PYELONEPHRITIS 48
    19. GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN
      1. OVERVIEW 49
      2. ESCHERICHIA COLI 50
      3. STAPHYLOCOCCUS SAPROPHYTICUS 51
      4. KLEBSIELLA PNEUMONIAE 51
      5. PROTEUS MIRABILIS 52
      6. ENTEROCOCCUS FAECALIS 52
    20. GLOBAL URINARY TRACT INFECTION MARKET
    21. BY END USER
      1. OVERVIEW 53
      2. HOSPITALS 54
    22. CLINICS 54
      1. SELF-ADMINISTERED 55
    23. GLOBAL URINARY TRACT
    24. INFECTION MARKET BY REGION
      1. OVERVIEW 56
      2. AMERICAS
        1. NORTH AMERICA 61
    25. CANADA 67
      1. LATIN AMERICA 70
      2. EUROPE 73
        1. WESTERN EUROPE 76
        2. EASTERN EUROPE
      3. ASIA-PACIFIC 101
        1. CHINA 105
    26. INDIA 108
      1. JAPAN 111
        1. AUSTRALIA 114
    27. SOUTH KOREA 117
      1. REST OF ASIA-PACIFIC 120
      2. MIDDLE
    28. EAST & AFRICA 123
      1. MIDDLE EAST 126
        1. AFRICA
    29. COMPETITIVE LANDSCAPE
      1. OVERVIEW 132
    30. COMPETITIVE BENCHMARKING 133
      1. GLOBAL URINARY TRACT INFECTION MARKET:
    31. COMPANY RANKING, 2020 134
      1. KEY DEVELOPMENTS & GROWTH STRATEGIES
        1. PRODUCT APPROVALS AND LAUNCHES 134
        2. ACQUISITIONS
      2. FINANCIAL MATRIX 135
    32. COMPANY PROFILES
      1. PFIZER INC. 136
        1. COMPANY OVERVIEW 136
    33. FINANCIAL OVERVIEW 137
      1. PRODUCTS/SERVICES OFFERED 138
        1. KEY DEVELOPMENTS 138
        2. SWOT ANALYSIS 138
    34. KEY STRATEGIES 139
      1. NOVO NORDISK A/S 140
        1. COMPANY
    35. OVERVIEW 140
      1. FINANCIAL OVERVIEW 140
        1. PRODUCTS/SERVICES
    36. OFFERED 141
      1. KEY DEVELOPMENTS 141
        1. SWOT ANALYSIS
        2. KEY STRATEGIES 141
      2. NOVARTIS AG 142
        1. COMPANY OVERVIEW 142
        2. FINANCIAL OVERVIEW 142
        3. PRODUCTS/SERVICES OFFERED 143
        4. KEY DEVELOPMENTS 143
        5. SWOT ANALYSIS 143
        6. KEY STRATEGIES 144
    37. MERCK & CO., INC. 145
      1. COMPANY OVERVIEW 145
    38. FINANCIAL OVERVIEW 145
      1. PRODUCTS/SERVICES OFFERED 146
        1. KEY DEVELOPMENTS 146
        2. SWOT ANALYSIS 146
    39. KEY STRATEGIES 146
      1. ELI LILY AND COMPANY 147
        1. COMPANY
    40. OVERVIEW 147
      1. FINANCIAL OVERVIEW 147
        1. PRODUCTS/SERVICES
    41. OFFERED 148
      1. KEY DEVELOPMENTS 148
        1. SWOT ANALYSIS
        2. KEY STRATEGIES 148
      2. ALLERGAN 149
    42. COMPANY OVERVIEW 149
      1. FINANCIAL OVERVIEW 149
    43. PRODUCTS/SERVICES OFFERED 150
      1. KEY DEVELOPMENTS 150
    44. SWOT ANALYSIS 150
      1. KEY STRATEGIES 150
      2. CIPLA INC.
        1. COMPANY OVERVIEW 151
        2. FINANCIAL OVERVIEW
        3. PRODUCTS/SERVICES OFFERED 151
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS 152
        6. KEY STRATEGIES 152
      3. TEVA PHARMACEUTICALS 153
        1. COMPANY OVERVIEW 153
        2. FINANCIAL OVERVIEW 153
        3. PRODUCTS/SERVICES OFFERED
        4. KEY DEVELOPMENTS 154
        5. SWOT ANALYSIS 154
        6. KEY STRATEGIES 155
      4. GLAXOSMITHKLINE PLC 156
        1. COMPANY OVERVIEW 156
        2. FINANCIAL OVERVIEW 156
        3. PRODUCTS/SERVICES OFFERED 157
        4. KEY DEVELOPMENTS 157
        5. SWOT ANALYSIS 157
        6. KEY STRATEGIES 157
    45. BAYER AG 158
      1. COMPANY OVERVIEW 158
        1. COMPANY
    46. VALUE 158
      1. FINANCIAL OVERVIEW 159
        1. PRODUCTS/SERVICES
    47. OFFERED 159
      1. KEY DEVELOPMENTS 159
        1. SWOT ANALYSIS
        2. KEY STRATEGIES 160
    48. APPENDIX
    49. REFERENCES 161
      1. RELATED REPORTS 161
    50. LIST OF TABLES
    51. INTERVIEWS AND INFORMATION GATHERING PROCESS 23
    52. TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 41
    53. GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY REGION, 2020-2027 (USD
    54. MILLION) 42
    55. BY TYPE, 2020-2027 (USD MILLION) 42
    56. MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY REGION, 2020-2027 (USD MILLION)
    57. CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 43
    58. TRACT INFECTION MARKET, FOR AMINOGLYCOSIDES, BY REGION, 2020-2027 (USD MILLION)
    59. REGION, 2020-2027 (USD MILLION) 44
    60. MARKET, FOR AZOLES, BY REGION, 2020-2027 (USD MILLION) 45
    61. URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 47
    62. (USD MILLION) 47
    63. CYSTITIS, BY REGION, 2020-2027 (USD MILLION) 48
    64. TRACT INFECTION MARKET, FOR PYELONEPHRITIS, BY REGION, 2020-2027 (USD MILLION) 48
    65. MILLION) 50
    66. COLI, BY REGION, 2020-2027 (USD MILLION) 50
    67. INFECTION MARKET, FOR STAPHYLOCOCCUS SAPROPHYTICUS, BY REGION, 2020-2027 (USD MILLION)
    68. BY REGION, 2020-2027 (USD MILLION) 51
    69. MARKET, FOR PROTEUS MIRABILIS, BY REGION, 2020-2027 (USD MILLION) 52
    70. GLOBAL URINARY TRACT INFECTION MARKET, FOR ENTEROCOCCUS FAECALIS, BY REGION,
    71. 2027 (USD MILLION) 52
    72. BY END USER, 2020-2027 (USD MILLION) 54
    73. INFECTION MARKET, FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION) 54
    74. (USD MILLION) 54
    75. SELF-ADMINISTERED, BY REGION, 2020-2027 (USD MILLION) 55
    76. URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 57
    77. AMERICAS: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION)
    78. 2027 (USD MILLION) 58
    79. MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 59
    80. AMERICAS: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS,
    81. BY TYPE, 2020-2027 (USD MILLION) 59
    82. INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60
    83. AMERICAS: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 60
    84. (USD MILLION) 60
    85. BY COUNTRY, 2020-2027 (USD MILLION) 61
    86. TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 61
    87. NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027
    88. (USD MILLION) 62
    89. FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 62
    90. (USD MILLION) 63
    91. BY PATHOGEN, 2020-2027 (USD MILLION) 63
    92. TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 63
    93. NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD
    94. MILLION) 64
    95. BY TYPE, 2020-2027 (USD MILLION) 64
    96. MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION)
    97. (USD MILLION) 65
    98. 2027 (USD MILLION) 66
    99. BY END USER, 2020-2027 (USD MILLION) 66
    100. INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 67
    101. CANADA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD
    102. MILLION) 67
    103. & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 68
    104. URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 68
    105. (USD MILLION) 69
    106. BY DRUG CLASS, 2020-2027 (USD MILLION) 70
    107. TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 70
    108. CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 71
    109. URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 72
    110. (USD MILLION) 72
    111. BY END USER, 2020-2027 (USD MILLION) 72
    112. INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 73
    113. URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 73
    114. (USD MILLION) 74
    115. Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 74
    116. MILLION) 75
    117. 2027 (USD MILLION) 75
    118. BY END USER, 2020-2027 (USD MILLION) 75
    119. TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 76
    120. WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD
    121. MILLION) 77
    122. FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 77
    123. EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS,
    124. BY TYPE, 2020-2027 (USD MILLION) 78
    125. TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78
    126. WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION)
    127. 2027 (USD MILLION) 79
    128. MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 80
    129. TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 80
    130. BY TYPE, 2020-2027 (USD MILLION) 81
    131. MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 81
    132. URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 82
    133. MILLION) 82
    134. CLASS, 2020-2027 (USD MILLION) 83
    135. MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 83
    136. FRANCE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS,
    137. BY TYPE, 2020-2027 (USD MILLION) 84
    138. MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 84
    139. TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 85
    140. FRANCE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION)
    141. (USD MILLION) 86
    142. BY TYPE, 2020-2027 (USD MILLION) 86
    143. MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION)
    144. (USD MILLION) 87
    145. 2027 (USD MILLION) 88
    146. BY END USER, 2020-2027 (USD MILLION) 88
    147. INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 89
    148. ITALY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION)
    149. & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 90
    150. URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90
    151. (USD MILLION) 91
    152. CLASS, 2020-2027 (USD MILLION) 92
    153. MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 92
    154. SPAIN: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY
    155. TYPE, 2020-2027 (USD MILLION) 93
    156. MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 93
    157. TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 94
    158. SPAIN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION)
    159. BY DRUG CLASS, 2020-2027 (USD MILLION) 95
    160. URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION)
    161. FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 96
    162. 2027 (USD MILLION) 96
    163. TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 97
    164. REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027
    165. (USD MILLION) 97
    166. BY DRUG CLASS, 2020-2027 (USD MILLION) 98
    167. TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 98
    168. CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 99
    169. EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    170. 2027 (USD MILLION) 100
    171. MARKET, BY END USER, 2020-2027 (USD MILLION) 100
    172. URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 101
    173. (USD MILLION) 102
    174. FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 102
    175. URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE,
    176. 2027 (USD MILLION) 103
    177. MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 103
    178. URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 104
    179. (USD MILLION) 104
    180. DRUG CLASS, 2020-2027 (USD MILLION) 105
    181. INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 105
    182. BY TYPE, 2020-2027 (USD MILLION) 106
    183. MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 106
    184. URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 107
    185. (USD MILLION) 108
    186. QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 108
    187. TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027
    188. (USD MILLION) 109
    189. APPLICATION, 2020-2027 (USD MILLION) 109
    190. INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 110
    191. INDIA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 110
    192. (USD MILLION) 111
    193. QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 111
    194. TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027
    195. (USD MILLION) 112
    196. APPLICATION, 2020-2027 (USD MILLION) 112
    197. INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 113
    198. JAPAN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 113
    199. (USD MILLION) 114
    200. FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 114
    201. URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE,
    202. 2027 (USD MILLION) 115
    203. MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 115
    204. URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 116
    205. MILLION) 116
    206. DRUG CLASS, 2020-2027 (USD MILLION) 117
    207. TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 117
    208. & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 118
    209. SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    210. 2027 (USD MILLION) 119
    211. MARKET, BY END USER, 2020-2027 (USD MILLION) 119
    212. URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 120
    213. BY TYPE, 2020-2027 (USD MILLION) 120
    214. URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE,
    215. 2027 (USD MILLION) 121
    216. INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121
    217. REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD
    218. MILLION) 122
    219. MARKET, BY END USER, 2020-2027 (USD MILLION) 122
    220. & AFRICA: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION)
    221. BY DRUG CLASS, 2020-2027 (USD MILLION) 123
    222. AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD
    223. MILLION) 124
    224. MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION)
    225. BY APPLICATION, 2020-2027 (USD MILLION) 125
    226. AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 125
    227. USER, 2020-2027 (USD MILLION) 125
    228. INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 126
    229. MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027
    230. (USD MILLION) 126
    231. FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 127
    232. (USD MILLION) 127
    233. BY PATHOGEN, 2020-2027 (USD MILLION) 128
    234. TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 128
    235. AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
    236. BY TYPE, 2020-2027 (USD MILLION) 129
    237. INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD
    238. MILLION) 130
    239. 2027 (USD MILLION) 130
    240. MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 131
    241. TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 131
    242. MAJOR MANUFACTURERS RANKING, 2020 134
    243. AND LAUNCHES 134
    244. INC.: PRODUCTS/SERVICES OFFERED 138
    245. OFFERED 141
    246. ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED 148
    247. PRODUCTS/SERVICES OFFERED 150
    248. OFFERED 151
    249. TEVA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154
    250. PHARMACEUTICALS: KEY DEVELOPMENTS 154
    251. PRODUCTS/SERVICES OFFERED 157
    252. LIST OF
    253. ANALYSIS, BY REGION, 2020 18
    254. MARKET: STRUCTURE 19
    255. (UTI) MARKET 29
    256. RESTRAINT IMPACT ANALYSIS 32
    257. INFECTION MARKET 33
    258. URINARY TRACT INFECTION MARKET 35
    259. MARKET, BY DRUG CLASS, 2020 AND 2027 (USD MILLION) 41
    260. URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 46
    261. (USD MILLION) 49
    262. END USER, 2020 AND 2027 (USD MILLION) 53
    263. INFECTION MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 57
    264. AMERICAS: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 58
    265. SHARE, BY COUNTRY, 2020 (%) 76
    266. INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 101
    267. & AFRICA: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 123
    268. OPERATING INCOME MARGIN, 2020 135
    269. EXPENDITURE, 2020 135
    270. NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 140
    271. SWOT ANALYSIS 141
    272. & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 145
    273. CO., INC.: SWOT ANALYSIS 146
    274. OVERVIEW SNAPSHOT 147
    275. ALLERGAN: SWOT ANALYSIS 150
    276. PLC: FINANCIAL OVERVIEW SNAPSHOT 156
    277. ANALYSIS 157

    Market Segmentation

    Urinary Tract Infection Market Drug Class Outlook (USD Billion, 2019-2030)

    • Quinolones
    • Beta & Cephalosporins
    • Aminoglycosides
    • Penicillin
    • Azoles

    Urinary Tract Infection Market Application Outlook (USD Billion, 2019-2030)

    • Urethritis
    • Cystitis
    • Pyelonephritis

    Urinary Tract Infection Market Pathogen Outlook (USD Billion, 2019-2030)

    • Escherichia coli
    • Staphylococcus saprophyticus
    • Klebsiella pneumoniae
    • Proteus mirabilis
    • Enterococcus faecalis

    Urinary Tract Infection Market End-User Outlook (USD Billion, 2019-2030)

    • Hospitals
    • Clinics
    • Self-Administered

    Urinary Tract Infection Market Regional Outlook (USD Billion, 2019-2030)

    • North America Outlook (USD Billion, 2019-2030)

      • North America Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • North America Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • North America Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • North America Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • US Outlook (USD Billion, 2019-2030)

      • US Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • US Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • US Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • US Urinary Tract Infection Market by End User
        • Hospitals
        • Clinics
        • Self-Administered
      • CANADA Outlook (USD Billion, 2019-2030)

      • CANADA Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • CANADA Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • CANADA Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • CANADA Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
    • Europe Outlook (USD Billion, 2019-2030)

      • Europe Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Europe Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Europe Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Europe Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Germany Outlook (USD Billion, 2019-2030)

      • Germany Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Germany Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Germany Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Germany Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • France Outlook (USD Billion, 2019-2030)

      • France Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • France Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • France Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • France Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • UK Outlook (USD Billion, 2019-2030)

      • UK Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • UK Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • UK Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • UK Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • ITALY Outlook (USD Billion, 2019-2030)

      • ITALY Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • ITALY Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • ITALY Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • ITALY Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • SPAIN Outlook (USD Billion, 2019-2030)

      • Spain Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Spain Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Spain Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Spain Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Rest Of Europe Outlook (USD Billion, 2019-2030)

      • Rest Of Europe Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • REST OF EUROPE Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • REST OF EUROPE Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • REST OF EUROPE Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
    • Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Asia-Pacific Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Asia-Pacific Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Asia-Pacific Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Asia-Pacific Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • China Outlook (USD Billion, 2019-2030)

      • China Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • China Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • China Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • China Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Japan Outlook (USD Billion, 2019-2030)

      • Japan Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Japan Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Japan Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Japan Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • India Outlook (USD Billion, 2019-2030)

      • India Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • India Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • India Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • India Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Australia Outlook (USD Billion, 2019-2030)

      • Australia Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Australia Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Australia Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Australia Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Rest of Asia-Pacific Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Rest of Asia-Pacific Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Rest of Asia-Pacific Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Rest of Asia-Pacific Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
    • Rest of the World Outlook (USD Billion, 2019-2030)

      • Rest of the World Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Rest of the World Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Rest of the World Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Rest of the World Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Middle East Outlook (USD Billion, 2019-2030)

      • Middle East Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Middle East Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Middle East Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Middle East Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Africa Outlook (USD Billion, 2019-2030)

      • Africa Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Africa Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Africa Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Africa Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
      • Latin America Outlook (USD Billion, 2019-2030)

      • Latin America Urinary Tract Infection Market by Drug Class
        • Quinolones
        • Beta & Cephalosporins
        • Aminoglycosides
        • Penicillin
        • Azoles
      • Latin America Urinary Tract Infection Market by Application
        • Urethritis
        • Cystitis
        • Pyelonephritis
      • Latin America Urinary Tract Infection Market by Pathogen
        • Escherichia coli
        • Staphylococcus saprophyticus
        • Klebsiella pneumoniae
        • Proteus mirabilis
        • Enterococcus faecalis
      • Latin America Urinary Tract Infection Market by End-User
        • Hospitals
        • Clinics
        • Self-Administered
    Urinary Tract Infection Market Research Report - Global Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials